Development of a New HPLC Method for the Determination of Lispro and Glargine Insulin Analogues in Pharmaceutical Preparations

Abstract
A rapid, accurate and sensitive HPLC method has been developed and validated for the quantitative determination of lispro and glargine insulin analogues in pharmaceutical preparations. Pharmacopeial method for the determination of insulin lispro employed mobile phase constituted by phosphate buffer solution 0.1 mol/L (pH 2.3) and acetonitrile (74 + 26, v/v) and flow rate of 0.8 mL/min. Retention time was estimated to be 25 minutes and the temperature of the column maintained to 40°C. No pharmacopeial method was found to the determination of insulin glargine. For this reason, the aim of this study was to develop and validate a new chromatographic method for the determination of lispro and glargine insulin analogues in pharmaceutical preparations. Solutions were prepared using the mobile phase (methanol-water, 70:30) as solvent and filtered through a 0.2 µm membrane. Aliquots of 20 µL were injected into the HPLC. The method validation parameters yielded good results and included range, linearity, precision, accuracy, specificity, and recovery. The calibration curves for lispro and glargine insulin analogues were linear from 0.1 to 3.5 UI/mL, with correlation coefficients of 0.9990 and 0.9995, respectively. The interday and intraday precisions (relative standard deviation) were less than 1%. The accuracy was studied and the recovery test indicated mean absolute of 100.99% and 98.76% for lispro and glargine insulin analogues, respectively. The results obtained by HPLC method were calculated by analysis of variance (ANOVA). We concluded that the HPLC method proposed is satisfactory for the quantification of lispro and glargine insulin analogues in pharmaceutical preparations.

Keywords: Insulin analogues; HPLC method validation; Quality control

Introduction
Insulin is a polypeptide hormone synthesized by the beta cells of the lest of Langerhans in pancreas. It is the major anabolic hormone participating in the regulation of homeostasis [1-5]. The insulin analogues are an altered type of insulin which perform action as human insulin in terms of glycemic control [6-8]. They are obtained by genetic engineering through alterations in the natural amino acid sequence of human insulin, changing its absorption, distribution, metabolism, and excretion [9-12]. Lispro and glargine are types of insulin analogues (rapid and long-acting, respectively) commercialized for subcutaneous administration. In brazil lispro insulin is commercialized under the brand name Humalog®, by Eli Lilly do Brasil, and glargine under the brand name Lantus® by Sanofi-Aventis Ltda [13,14].

Several analytical procedures are available in the literature for the analysis of insulin and its analogues. These methods are immunoassay [15-18], high performance liquid chromatography [19-25], and mass spectrometry [26-30]. According to the pharmacopeial method for the determination of insulin lispro, the mobile phase is constituted by phosphate buffer solution 0.1 mol/L (pH 2.3) and acetonitrile. Retention time (Rt) is estimated to be 25 minutes and the temperature of the column maintained to 40°C (19-23). No pharmacopeial method was found to the determination of glargine insulin.

The development of methods in HPLC for the determination of drugs has received considerable attention in recent years because of their importance in quality control in pharmaceutical analysis. Pharmacopeial assays still rely quite heavily on direct UV spectroscopy but in quality control the detection by UV spectrophotometry is usually combined with a preliminary separation by HPLC [31]. Ideally, the buffer should transmit light at or below 220 nm so as to allow low-UV detection. All of the buffers, except citrate meet this criterion. However, buffer absorbance at low wavelengths can be strongly increased by the presence of impurities. Some buffers degrade on standing and may increase their UV absorbance during storage on long-term use, and are able to interact with
the sample or the stationary phase by means of ion pairing. It should be noted that a change in buffer could result in a change in selectivity [32,33].

In this work, the parameters developed for the determination of insulin analogues did not employ buffer; and the mobile phase (methanol/water; 70:30) used is simple and advantageous; the most quality control applications can be carried out with methanol/water as a mobile phase.

For this reason, the purpose of the present work was to describe the development and validation of the simple and accurate HPLC method for the analysis of lispro and glargine insulin analogues in pharmaceutical preparations.

Materials and Methods

Samples

Insulin lispro (Lot9074) and glargine insulin (Lot73A) reference solutions with assigned purity of 100UI/mL as well the pharmaceutical preparations (injections) were generously donated by Eli Lily (São Paulo, Brazil) and Sanofi-Aventis Ltda (São Paulo, Brazil). Insulin lispro injection was claimed to contain 100UI/mL of drug and glycerol, metacresol, sodium phosphate, zinc oxide and water as excipient. Insulin glargine injection was claimed to contain 100UI/mL of drug and glycerol, cresol, hydrochloric acid, sodium hydroxide, zinc chloride and water as excipient. The reference solutions, as well as the pharmaceutical preparations (injections), were always kept protected from light and stored at refrigerator (8°C).

Reagents and solvents

All other chemicals used were of pharmaceutical or special analytical grade. Distilled water purified using a Milli-Q system (Millipore, Milford, MA). All solutions were filtered through a membrane of 0.2 µm pore size (Hexis, Brazil).

Apparatus and chromatographic conditions

Quantitative HPLC was performed on a Waters Binary HPLC Model 1525 chromatograph equipped with a variable-wavelength detector (set at 214 nm) and injection valve with a 20µL loop. The analytical column was a C18 Wat 054275 (150 mm x 4.6 mm id, 5µm particle size) column. The mobile phase used was methanol/water (70:30, v/v). All analyses were done under isocratic conditions at a flow-rate of 1.0mL/min and at room temperature. The sensitivity was 0.5 AUFS and the chart speed 0.5cm/min (Table 1). The HPLC system was operated at ambient temperature (20 ± 1°C). The mobile phase was degassed for 15 minutes and vacuum filtered through 0.2µm x 47mm filtration membrane (Hexis, Brazil). The analysis required 5 minutes.

Procedure

Preparation of lispro and glargine insulin analogues (reference solutions): Aliquots of 5.0mL of the lispro and glargine insulin analogues reference solutions (100UI/mL) were transferred to 50mL volumetric flasks and the volume was completed with the mobile phase (methanol/water, 70:30) used is simple and advantageous; the most quality control applications can be carried out with methanol/water as a mobile phase. The reference solutions, as well as the pharmaceutical preparations (injections), were always kept protected from light and stored at refrigerator (8°C).

Procedure

Preparation of lispro and glargine insulin analogues (reference solutions): Aliquots of 5.0mL of the lispro and glargine insulin analogues reference solutions (100UI/mL) were transferred to 50mL volumetric flasks and the volume was completed with the mobile phase (methanol/water, 70:30) used is simple and advantageous; the most quality control applications can be carried out with methanol/water as a mobile phase. The reference solutions, as well as the pharmaceutical preparations (injections), were always kept protected from light and stored at refrigerator (8°C).

The method was validated by determination of the following operational characteristics: linearity, range, precision, specificity, and accuracy [34-36]. The accuracy and precision of the assay, as well as the linearity of the calibration curve, were determined intraday and interday on 3 different days. The precision was expressed as the relative standard deviation (RSD, %) of each curve. The statistical data were calculated by analysis of variance (ANOVA).

Linearity: In order to assess the validity of the assay, amounts of 5.0mL of lispro and glargine reference solutions were diluted in 50mL volumetric flasks and final volumes were completed with the mobile phase (10.0UI/mL). Appropriate aliquots of this solution were diluted with mobile phase, yielding concentrations of 0.1, 0.5, 1.0, 2.0, 3.0 and 3.5UI/mL for the calibration curves. The final concentration investigated was 2.0UI/mL, and 20µL were injected.

Table 1: HPLC conditions for determination of insulin lispro and insulin glargine in pharmaceutical preparations.

| Condition          | Method Selection          |
|--------------------|---------------------------|
| Mobile phase       | Methanol: Water (70:30)   |
| Column             | Waters C18 (WAT 054275)   |
| Wavelength         | 214nm                     |
| Flow rate          | 1.0mL/min                 |
| Detection          | 0.5AUFS                   |
| Injection volume   | 20.0µL                    |
| Temperature        | 22°C ± 1°C                |

Assay of lispro and glargine insulin analogues (pharmaceutical preparations): Aliquots of 5.0mL of the lispro and glargine insulin analogues (100UI/mL) were transferred to 50mL volumetric flasks and the volume was completed with the mobile phase (10.0UI/mL). So, aliquots of 0.1, 0.5, 1.0, 2.0, 3.0 and 3.5mL of the stock solutions (10.0UI/mL) were transferred to 10mL volumetric flasks, diluted to mark with the mobile phase and filtered, yielding concentrations of 0.1, 0.5, 1.0, 2.0, 3.0 and 3.5UI/mL for the calibration curves. The final concentration investigated was 2.0UI/mL, and 20µL were injected. The LOD and LOQ values were directly calculated by using

Citation: Moreno AH, Lucchesi MBB, Dib SA, Salgado HRN (2018) Development of a New HPLC Method for the Determination of Lispro and Glargine Insulin Analogues in Pharmaceutical Preparations. J Anal Pharm Res 7(1): 00195. DOI: 10.15406/japlr.2018.07.00195
Development of a New HPLC Method for the Determination of Lispro and Glargine Insulin Analogues in Pharmaceutical Preparations

The method was validated by evaluation of intraday and interday precision. In the range of 0.1-3.5UI/mL, the CV on the basis of the peak area ratios for 3 replicates injections were found to be between 0.08 to 1.98% for insulin lispro, and 0.07 to 1.03% for insulin glargine. The interday precision (3 days, n = 6) of the assay expressed as CV ranged from 0.55 to 0.59% for insulin lispro, and 0.56 to 0.79% for insulin glargine, respectively (Table 2 & 3). The mean absolute recovery determined by adding known amounts of reference solutions (0.1, 0.2 and 0.4UI/mL) to known concentrations of reference solutions (0.1, 0.2 and 0.4UI/mL) were 100.99% and 98.76% (lispro and glargine, respectively). The experimental values obtained for the determination of recovery are shown in Table 4 & 5. The CV of the symmetry and the peak area response were 2%. Recovery tests confirmed the accuracy of the proposed method.

Citation: Moreno AH, Lucchesi MBB, Dib SA, Salgado HRN (2018) Development of a New HPLC Method for the Determination of Lispro and Glargine Insulin Analogues in Pharmaceutical Preparations. J Anal Pharm Res 7(1): 00195. DOI: 10.15406/japlr.2018.07.00195
Development of a New HPLC Method for the Determination of Lispro and Glargine Insulin Analogues in Pharmaceutical Preparations

Table 2: Determination of insulin lispro in pharmaceutical preparations by the chromatographic proposed method in three different days.

| DAY | Mean inter-day |
|-----|----------------|
| I   | 99.90          |
| II  | 99.74          |
| III | 99.38          |
| IV  | 99.24          |
| V   | 99.67          |

Table 3: Determination of insulin glargine in pharmaceutical preparations by the chromatographic proposed method in three different days.

| DAY | Mean inter-Day |
|-----|----------------|
| I   | 99.32          |
| II  | 99.90          |
| III | 99.61          |
| IV  | 100.42         |
| V   | 100.88         |
| VI  | 100.37         |

The method exhibited good robustness because the changes made in chromatographic conditions did not influence the results obtained.

Table 4: Experimental values obtained in the recovery test for insulin lispro in pharmaceutical preparations, by HPLC proposed method.

| Added (UI/mL) | Found (UI/mL) | Recovery (%) | CV (%) |
|--------------|--------------|--------------|--------|
| R1           | 0.1          | 0.1005       | 100.50 |
|              |              | 0.1025       | 0.985  |
| R2           | 0.2          | 0.2095       | 101.92 |
|              |              | 0.2035       | 1.985  |
| R3           | 0.4          | 0.4025       | 100.54 |
|              |              | 0.3945       | 1.095  |

Table 5: Experimental values obtained in the recovery test for insulin glargine in pharmaceutical preparations, by HPLC proposed method.

| Added (UI/mL) | Found (UI/mL) | Recovery (%) | CV (%) |
|--------------|--------------|--------------|--------|
| R1           | 0.1          | 0.0987       | 99.37  |
|              |              | 0.1017       | 0.9975 |
| R2           | 0.2          | 0.2037       | 98.85  |
|              |              | 0.1987       | 1.907  |
| R3           | 0.4          | 0.3877       | 98.07  |
|              |              | 0.3854       | 0.937  |

Lispro and glargine insulin analogues in pharmaceutical preparations (injection) were analyzed, and the results obtained can be in Table 2 & 3. No interference from excipients could be observed at the detection wavelength (214nm), as shown in Figure 1. The method exhibited good robustness because the changes made in chromatographic conditions did not influence.

Figure 2: Calibration curves for insulin lispro (A) and insulin glargine (B), obtained by the HPLC proposed method.
the analytical results. Lispro and glargine insulin analogues were shown to be stable during the procedure.

Conclusion

The present study developed a rapid and precise method for the determination of lispro and glargine insulin analogues in pharmaceutical preparations (injection) by HPLC. The method demonstrated acceptable linearity, sensitivity, precision, and accuracy. The method use simple reagents with minimum sample preparation procedures and short analysis time, encouraging its application in routine analysis. The results indicate that the proposed method might be recommended for the quality control of lispro and glargine insulin analogues in pharmaceutical preparations.

Acknowledgement

The authors are grateful to Eli Lilly (São Paulo, Brazil) and Sanofi-Aventis Ltda. (São Paulo, Brazil) for providing lispro and glargine insulin reference solutions and pharmaceutical preparations. This work was supported by FAPESP (São Paulo, Brazil), Fundunesp (São Paulo, Brazil), CNPq (Brasilia, Brazil) program, PACD-FCF-UNESP (Araraquara, Brazil) and CAPES-PROEX (São Paulo, Brazil).

Conflict of Interest

The authors declare that there are no conflicts of interest.

References

1. Gayton AC, Hall JE (2017) Tratado de Fisiologia Médica. (13th edn), Rio de Janeiro, Guanabara Koogan, Brazil, pp. 1008.
2. Hardman JG, Limbird LE (2012) As Bases Farmacológicas da Terapêutica. (12th edn), Rio de Janeiro, Mc Graw Hill, Brazil, pp.1263-1289.
3. Martindale (2006) Guia Completa de Consulta Farmaco-Terapêutica. (2nd edn), Barcelona, Spain, pp. 1563.
4. Nichols WK (2004) Hormônios e antagonistas hormonais. In: Gennaro AR (Eds.), Remington: A Ciência e a Prática da Farmácia. (20th edn), Rio de Janeiro, pp.142-1451.
5. Silva P (2002) Farmacologia. Rio de Janeiro, Brazil, pp. 851.
6. Gilles PS, Figgitt DP, Lamb HM (2000) Insulin glargine. Drugs 59: 253-260.
7. Eyzaguirre F, Codner E (2006) Análogos de insulina: en busca del reemplazo fisiológico. Rev Méd Chil 134: 239-250.
8. Holleman F, Hoekstra J (1997) Insulin lispro. N England J Med 337: 176-183.
9. Thomas A, Schanzer W, Thevis M (2014) Determination of human insulin and its analogues in human blood using liquid chromatography coupled to ion mobility mass spectrometry (LC-IM-MS). Drug Test Analysis 6: 1125-1132.
10. Massry SG (2011) Sequence of cellular events in pancreatic islets leading to impaired insulin secretion in chronic kidney disease. J Ren Nutr 21(1):92-99.
11. Pasquier F (2010) Diabetes and cognitive impairment: how to evaluate the cognitive status? Diabetes Metab 36(3): 100-105.
12. Quintanilla-García C, Záñiga-Guajardo S (2010) The incretin effect and type 2 diabetes. Rev Med Inst Mex Seguro Soc 48(5): 503-508.
13. Fonseca AL (2009) Dicionário de Especialidades Farmacêuticas. (38th edn), Rio de Janeiro, Brazil, pp.730.
14. Barros E (2008) Medicamentos de A a Z. Porto Alegre, Artmed, pp. 280-281.
15. Deberg M, Houssa P, Frank BH, Sodoyez-Geffaux F, Sodoyez JC (1998) Highly specific radioimmunoassay for human insulin based on immune exclusion of all insulin precursors. Clinical Chemistry 44(7): 1504-1513.
16. Arquint H, Olsson PO, Von Schenck H (1987) Free and total insulin as determined after precipitation with polyethylene glycol: analytical characteristics and effects of samples handling and storage. Clin Chem 33(1): 93-96.
17. Sacks DB, Bruns DE, Oldstein DE, MacAren NK, Mcdonald JM, et al. (2002) Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 48(6): 436-472.
18. Kogkka MM, Brandão LP, Jericó MM, Hagiwara MK, Simões DMN, et al. (2001) Determinação das concentrações séricas de glicose e insulina em cães em choque endotóxico. Ciênc Rural 31(5): 813-817.
19. (2010) Farmacopeia Brasileira. (5th edn), Anvisa, Brasília, p. 36-40.
20. (2005) Farmacopeia Portuguesa. (8th edn), Infarmed, Lisboa, Portugal, pp. 311-317.
21. (2009), British Pharmacopeia. The Stationary Office, London, UK, pp. 3182-3188.
22. (2005) European Pharmacopeia. The Stationary Office, London, UK, pp. 1795-1800.
23. (2009) United States Pharmacopeia. (32nd edn), The United States Pharmacopeial Convention, Rockville, USA, pp. 1132-1138.
24. Mayasa V, Rasil VPK, Unger BS (2016) Method development and validation of insulin estimation in insulin degrading enzyme assay using RP-HPLC. Int J Chem Sci 14(3): 1520-1532.
25. Najjar A, Alawi M, Abuheshmah A, Sallam A (2014) A Rapid, Isocratic HPLC Method for Determination of Insulin and Its Degradation Product. Advances in Pharmaceutics 2014: 1-6.
26. Darby SM, Miller ML, Allen RO, Lebleau M (2001) A mass spectrometric method for quantitation of intact insulin in blood samples. J Anal Toxicol 25(1): 8-14.
27. Thevis M, Thomas A, Delahaut P, Bosseloir A, Schanzer W (2006) Doping control analysis of intact rapid-acting insulin analogues in human urine by liquid chromatography-tandem mass spectrometry. Anal Chem 78(6): 1897-1903.
28. Thevis M, Thomas A, Schanzer W (2008) Mass spectrometric determination of insulins and their degradation products in sports drug testing. Mass Spectrom Reviews 27(1): 35-50.
29. Thevis M, Thomas A, Delahaut P, Bosseloir A, Schanzer W (2005) Qualitative determination of synthetic analogues of insulin in human plasma by immunofinity partition and liquid chromatography-tandem mass spectrometry for doping control purposes. Anal Chem 77(11): 3579-3585.
30. Uttyfanghe KV, Cabaleiro DR, Stockl D, Thienpont LM (2007) New liquid chromatography/electrospray ionization tandem mass...
Development of a New HPLC Method for the Determination of Lispro and Glargine Insulin Analogues in Pharmaceutical Preparations

spectrometry measurement procedure for quantitative analysis of human insulin in serum. Mass Spectrom 21(5): 819-821.

31. Watson DG (1999) Pharmaceutical Analysis. Churchill Livingstone, London, UK, p. 75-96.

32. Snyder LR, Kirkland JJ, Glajch JL (1997) Practical HPLC method development. (2nd edn), John Wiley and Sons, New York, USA, pp. 292-316.

33. Ohannesian L, Streeter AJ (2002) Handbook of pharmaceutical analysis, Marcel Dekker, New York, USA, pp. 87-149.

34. (2000) Official Methods of Analysis. (17th edn), AOAC International, Gaithersburg, USA, pp. 150.

35. ICH (1997) Steering Committee. International Conference on harmonization of Technical Requirements for Registration of Pharmaceutical for Human Use Validation of Analytical Procedures: Methodology, Geneva, Switzerland.

36. (2003) Resolução RE n. 899, de 29 de maio de 2003. Determina a publicação do guia para validação de métodos analíticos e bioanalíticos, Diário Oficial da República Federativa do Brasil, Anvisa, Brasília.